News
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...
News
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...
News
Surgery may worsen pleural mesothelioma survival outcomes
The first randomized, controlled trial shows greater mortality than chemotherapy alone, though surgical expertise may be a confounder.
News
ADCs show early promise in NSCLC
“ADCs are a new, rapidly evolving class of therapeutics, and I think that we will all have to be prepared for the future that is coming,” said Dr...
News
What is the proper treatment for posttraumatic headache? Expert debate
Preventative treatment could reduce chronification, but has the potential to worsen comorbidities.
News
Prodrome treatment with ubrogepant prevents migraines
Intervention also reduced prodromal symptoms in patients who could reliably predict oncoming headaches.
News
Migraine treatment with rimegepant linked to reduced barbiturate use
Real-world analysis suggests potential for improvements in medication overuse and dependency.
News
Migraine device expands treatment possibilities
New studies of remote electrical neuromodulation show efficacy in adolescents and safety during pregnancy.
Article
Cannabis RCT shows efficacy, AEs in migraine
First RCT in migraine suggests THC/CBD mix might be best, and that recreational doses may be higher than necessary.
News
Migraine clusters emerge from machine-learning analysis
Groupings somewhat reflect expert consensus, but also suggest therapeutic avenues.
News
New study backs up capecitabine dosing practice in metastatic BC
Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.
News
In TNBC, repeated biopsies may reveal emergent HER2-low expression
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
News
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
News
Review may help clinicians treat adolescents with depression
“We did two systematic reviews to look at the continuing professional development of family physicians in adolescent health, and it turned out...
News
Metronomic chemotherapy performs well in second-line head and neck cancer
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.